RxDoctor Payments Data

Luis del Prado, MD

Family Medicine · Miami, FLNPI 1619230612

Payments from drug & device makers

$1,141,841in general payments, 2019–2025

Across 346 payments — averaging $3300.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$450K
  • Alnylam Pharmaceuticals Inc.$422K
  • Abbott$173K
  • Bausch Health US, LLC$66K
  • Novartis$22K
  • Vertex$9K
  • plus $118 from 2 others
$6,128in research payments, 2019–2025

Across 2 payments — averaging $3064.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$6K

What the payments were for

  • Food & beverage$118100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly7$450,055
Alnylam Pharmaceuticals Inc.272$421,617
Abbott46$173,098
Bausch Health US, LLC14$65,575
Novartis1$22,074
Vertex2$9,304
Lilly USA, LLC2$92
Johnson & Johnson2$26

How this compares

$1,141,841 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$308,946
Medicare patients
415
Services billed
3,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban302$96,418
JardianceEmpagliflozin88$35,454
TrulicityDulaglutide41$23,971
OzempicSemaglutide25$23,827
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog127$20,177
EntrestoSacubitril/Valsartan36$16,944
Fiasp FlextouchInsulin Aspart (Niacinamide)78$16,162
FarxigaDapagliflozin Propanediol22$11,921
FiaspInsulin Aspart (Niacinamide)38$11,893
Memantine Hcl145$7,603
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,996
JanumetSitagliptin Phos/Metformin Hcl13$6,616
BrilintaTicagrelor19$6,253
Atorvastatin Calcium448$5,081
Tresiba Flextouch U-100Insulin Degludec18$4,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Humalog$92$26,12381 claims
NovartisEntresto$22,074$16,94436 claims
Johnson & JohnsonXarelto$26$4,57312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →